{"url":"https://lda.senate.gov/api/v1/filings/7c74bb11-c1d2-4efb-8f4e-bc3bc4c705e8/","filing_uuid":"7c74bb11-c1d2-4efb-8f4e-bc3bc4c705e8","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2021,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/7c74bb11-c1d2-4efb-8f4e-bc3bc4c705e8/print/","filing_document_content_type":"text/html","income":"90000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Elizabeth Ray","dt_posted":"2022-01-19T14:25:57.567000-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"100 M Street, SE","registrant_address_2":"Suite 750","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20003","registrant":{"id":400534596,"url":"https://lda.senate.gov/api/v1/registrants/400534596/","house_registrant_id":41161,"name":"THORN RUN PARTNERS","description":"Government Affairs Firm","address_1":"100 M Street, SE","address_2":"Suite 750","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20003","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"W. CHRISTOPHER LAMOND","contact_telephone":"+1 202-688-0225","dt_updated":"2026-07-09T09:06:40.882848-04:00"},"client":{"id":192638,"url":"https://lda.senate.gov/api/v1/clients/192638/","client_id":1472,"name":"THE BIOSIMILARS FORUM","general_description":"Non-profit Organization","client_government_entity":false,"client_self_select":null,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2019-01-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Medicare reimbursement issues. FDA regulations of biosimilars.\nIssues related to Drug Pricing Reduction and increasing access to Biosimilars.  \nDepartments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2022\nH.R. 2815, BIOSIM Act\nH.R. 2855, Star Rating for Biosimilars Act. \nH.R. 2869, Increasing Access to Biosimilars Act of 2021.\nS. 1427, Increasing Access to Biosimilars Act of 2021.\nBuild Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.","foreign_entity_issues":"Boehringer Ingelheim GmbH, Merck KGaA, Novartis AG, Samsung Bioepis, Teva Pharmaceutical Industries Ltd., as identified on LD-1, are dues paying coalition members.","lobbyists":[{"lobbyist":{"id":64036,"prefix":null,"prefix_display":null,"first_name":"STUART","nickname":null,"middle_name":null,"last_name":"CHAPMAN","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, Representative Carolyn McCarthy; Chief of Staff, Representative Zack Space; Press Secretary, Senator Jay Rockefeller; Press Secretary, Representative Barbara Lee","new":false},{"lobbyist":{"id":56748,"prefix":null,"prefix_display":null,"first_name":"ALEX","nickname":null,"middle_name":null,"last_name":"DELPIZZO","suffix":null,"suffix_display":null},"covered_position":"Legislative Director/Legislative Asst, Rep. Ferguson; Staff Asst, House Transportation and Infrastructure Committee","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Drug pricing legislation.\nIssues related to Drug Pricing Reduction and increasing access to Biosimilars. \nDepartments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2022.\nH.R. 2815, BIOSIM Act\nH.R. 2855, Star Rating for Biosimilars Act. \nH.R. 2869, Increasing Access to Biosimilars Act of 2021.\nS. 1427, Increasing Access to Biosimilars Act of 2021. \nBuild Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.","foreign_entity_issues":"Boehringer Ingelheim GmbH, Merck KGaA, Novartis AG, Samsung Bioepis, Teva Pharmaceutical Industries Ltd., as identified on LD-1, are dues paying coalition members.","lobbyists":[{"lobbyist":{"id":64036,"prefix":null,"prefix_display":null,"first_name":"STUART","nickname":null,"middle_name":null,"last_name":"CHAPMAN","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, Representative Carolyn McCarthy; Chief of Staff, Representative Zack Space; Press Secretary, Senator Jay Rockefeller; Press Secretary, Representative Barbara Lee","new":false},{"lobbyist":{"id":56748,"prefix":null,"prefix_display":null,"first_name":"ALEX","nickname":null,"middle_name":null,"last_name":"DELPIZZO","suffix":null,"suffix_display":null},"covered_position":"Legislative Director/Legislative Asst, Rep. Ferguson; Staff Asst, House Transportation and Infrastructure Committee","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}